Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Marrow failure.

Alan D D'Andrea1, Niklas Dahl, Eva C Guinan

  • 1Dana-Farber Cancer Institute, Department of Pediatrics Oncology, Boston, MA 02115, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct and indirect regulation of fetal globin transcript by RNA-binding protein IGF2BP1.

Blood·2026
Same author

Beyond neutropenia: Immunological evaluation of patients with Shwachman-Diamond syndrome.

British journal of haematology·2026
Same author

USP1 inhibition promotes RAD18-dependent PCNA degradation and BRCA1 synthetic lethality.

bioRxiv : the preprint server for biology·2026
Same author

Liver stiffness in patients with Shwachman-Diamond syndrome.

JPGN reports·2026
Same author

Timing is everything: age-dependent cancer risk in RUNX1-FPD.

Blood advances·2026
Same author

High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia.

Nature genetics·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

This chapter details Fanconi anemia (FA) and Diamond-Blackman anemia (DBA), focusing on their clinical and molecular aspects. It also updates on diagnosing and treating pediatric bone marrow failure, including aplastic anemia.

Area of Science:

  • Hematology
  • Genetics
  • Pediatric Medicine

Background:

  • Bone marrow failure syndromes (BMFS) encompass inherited and acquired conditions affecting blood cell production.
  • Fanconi anemia (FA) and Diamond-Blackfan anemia (DBA) are distinct inherited BMFS with unique clinical and molecular underpinnings.
  • Accurate diagnosis and timely treatment are critical for improving outcomes in pediatric patients with BMFS.

Purpose of the Study:

  • To describe the clinical presentation and molecular basis of Fanconi anemia (FA) and Diamond-Blackfan anemia (DBA).
  • To provide an updated overview of diagnostic and therapeutic strategies for all types of bone marrow failure in pediatric patients.
  • To highlight recent advances in understanding FA and DBA pathogenesis and their implications for patient care.

Main Methods:

Related Experiment Videos

  • Review of clinical manifestations and molecular pathogenesis of FA.
  • Examination of clinical features and molecular pathogenesis of DBA, including the role of the RPS19 gene.
  • Development of a diagnostic and treatment algorithm for inherited and acquired aplastic anemia in children, supported by a case study.

Main Results:

  • Significant advances in understanding FA molecular pathogenesis have led to new diagnostic assays and treatment options.
  • The RPS19 gene is considered in relation to the erythropoiesis defect in DBA.
  • An updated approach to the diagnosis and management of pediatric bone marrow failure, including aplastic anemia, is presented.

Conclusions:

  • Comprehensive understanding of FA and DBA molecular basis is crucial for improved diagnostics and therapeutics.
  • A systematic approach to diagnosis and treatment is essential for managing pediatric bone marrow failure syndromes.
  • Ongoing research continues to refine our understanding and management of inherited and acquired bone marrow failure.